Expert Interview
Discussing the CD123 from Immunogen, Pivekimab Sunirine, and its potential in AML when used in combination with azacitidine and/or venetoclax
Ticker(s): IMGNInstitution: Fred Hutchinson Cancer Center
- Professor in the clinical research division, Endowed Chair for Cancer Research at Fred Hutchinson Cancer Center & Professor of Medicine at the University of Washington.
- Currently manages over 50 patients with AML.
- Research involves developing improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate AML stem cells.
4. We'd like to focus now on Pivekimab sunirine (PVEK, ADC targeting CD123). The company (Immunogen) will present updated PhIb/II data at the upcoming ASH meeting - combinations use with venetoclax/azacitidine. Could you please comment on what would be here a competitive efficacy/safety profile? What would spark your interest on the ORR front? What shall we be looking for regarding safety / tolerability in this triplet?
6. What do you think about the data Immunogen reported in r/rAML?
1. Could you please give us a brief description of your background and your praxis?
2. Could you please guide us through the current treatment algorithm for the 1st line AML, unfit patients?
3 What remains the key unmet medical need for the 1st line AML unfit patients?
5. What do you think about CD123 as a target in AML?
How do you see treatment algorithm changing in the 1st line AML over the next 5 years? Are there any assets in development that you are monitoring?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
